Literature DB >> 21284348

Rhinocerebral mucormycosis: an update.

A Mallis1, S N Mastronikolis, S S Naxakis, A T Papadas.   

Abstract

BACKGROUND AND OBJECTIVES: Mucormycoses are a group of invasive infections caused by filamentous fungi of the Mucoraceae family, with the rhinocerebral form of the disease being the most common in large case series. In the present paper we review the characteristics of the rhinocerebral form of the disease. EVIDENCE AND INFORMATION SOURCES: The present review is based on the analysis of the current literature on rhinocerebral mucormycosis. STATE OF THE ART: Rhinocerebral mucormycosis is associated with immunocompromised patient state, haemochromatosis, desferrioxamine therapy and prolonged corticosteroid therapy. Uncontrolled diabetes and increased serum iron are regarded as the two leading predisposing factors for the development of the disease. Currently, treatment for the disease is based on three main principles; rapid reversal of underlying predisposing factors, antifungal therapy with amphotericin B and timely surgical intervention. PERSPECTIVES: Antifungal drugs of the azole group and new iron chelating agents--deferasirox, deferiprone--have been supported as alternative options to amphotericin B or as salvage therapy.
CONCLUSIONS: Rhinocerebral mucormycosis requires a high level of awareness if early diagnosis and treatment is to be achieved. Large scale evaluation of arising treatment options is a mandatory course of action in the future research of the disease.

Entities:  

Mesh:

Year:  2010        PMID: 21284348

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  Rhinocerebral mucormycosis--a case report.

Authors:  Shaji Thomas; V Dal Singh; Yuvaraj Vaithilingam; Sumeeth Cyriac Thayil; Rohit Kothari
Journal:  Oral Maxillofac Surg       Date:  2011-09-28

2.  Fungal Orbital Cellulitis: Presenting Features, Management and Outcomes at a Referral Center.

Authors:  Asim V Farooq; Rakesh M Patel; Amy Y Lin; Pete Setabutr; Juliana Sartori; Vinay K Aakalu
Journal:  Orbit       Date:  2015-04-23

Review 3.  Rhinocerebral mucormycosis in a patient with type 1 diabetes presenting as toothache: a case report from Himalayan region of India.

Authors:  Vikram Singh; Mridu Singh; Chitra Joshi; Jyoti Sangwan
Journal:  BMJ Case Rep       Date:  2013-10-30

4.  Rhinocerebral mucormycosis in a diabetic case report.

Authors:  Sm Oladeji; Yb Amusa; Jk Olabanji; Ao Adisa
Journal:  J West Afr Coll Surg       Date:  2013-01

5.  Rhino-orbital mucormycosis in diabetes mellitus.

Authors:  Ravindra V Shinde; Geeta S Karande; S T Mohite; S R Patil
Journal:  J Clin Diagn Res       Date:  2013-06-01

6.  Rhinomaxillary mucormycosis with palatal perforation: a case report.

Authors:  G Sreenath; A Ravi Prakash; M Rajni Kanth; P Sreenivas Reddy; Pavani Vidhyadhari
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 7.  The impact of diabetes on the pathogenesis of sepsis.

Authors:  G C K W Koh; S J Peacock; T van der Poll; W J Wiersinga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

8.  Fungal Rhino-orbital Cerebritis in a Patient with Steroid-induced Ketoacidosis.

Authors:  Carrie Vargo; Beth-Ann Olliviere-Baptiste; Jay M Brenner; Derek R Cooney; Elliot Rodriguez
Journal:  Clin Pract Cases Emerg Med       Date:  2018-09-18

9.  Clinical features and outcome of mucormycosis.

Authors:  Carlos Rodrigo Camara-Lemarroy; Emmanuel Irineo González-Moreno; René Rodríguez-Gutiérrez; Erick Joel Rendón-Ramírez; Ana Sofía Ayala-Cortés; Martha Lizeth Fraga-Hernández; Laura García-Labastida; Dionicio Ángel Galarza-Delgado
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-08-20

10.  Combination of amphotericin B and caspofungin in the treatment of mucormycosis.

Authors:  Marwa Gargouri; Chakib Marrakchi; Wiem Feki; Slim Charfi; Imed Maaloul; Dorra Lahiani; Emna Elleuch; Makram Koubaa; Zineb Mnif; Ali Ayadi; Tahiya Boudawara; Mounir Ben Jemaa
Journal:  Med Mycol Case Rep       Date:  2019-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.